Nel ASA

Board/Management Information • Mar 20, 2014

New CEO

New CEO

Lars Christian Stugaard (32) has been appointed as acting Chief

Executive Officer (CEO) of DiaGenic ASA on an interim basis effective

from 1st April 2014. Mr. Stugaard holds the position as CEO in Strata

Marine & Offshore AS and has worked in the Ferncliff group since 2003.

During his 11 year tenure with Ferncliff, he has been working with

financial management, general business development and analysis. He

holds a BSc from the Norwegian School of Management in Oslo.

Contact:

Hanne Skaarberg Holen, Chairman of the Board, +47 982 94 591

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to

create value for patients, partners and investors by developing

innovative and patient friendly in vitro diagnostic (IVD) products for

early detection of diseases. The company's proprietary concept implies

that a disease evokes systemic responses in the blood unique for the

disease, and which can be measured by using a blood sample. DiaGenic is

a world leader in identifying gene expression signatures in blood and is

focused on the development of IVD biomarker products in the field of

Alzheimer's disease. The company protects its technology through an

extensive patent portfolio. DiaGenic is listed on the Oslo Stock

Exchange. For more information please visit: www.diagenic.com